Results 191 to 200 of about 10,598 (216)

173P Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer

2022
BackgroundFusions in the neurotrophic tyrosine receptor kinase (NTRK) genes act as oncogenic drivers in many solid tumours, including secretory and non-secretory breast cancers. In the phase 2 STARTRK-2 clinical trial (NCT02568267), entrectinib (a TRK inhibitor with CNS activity) induced objective responses in 83.3% of patients (pts) with NTRK-fp ...
Lu, J., Blakely, C.M., Barve, M., Chung, C.H., Waqar, S.N., Hu, X., Delord, J-P., Krzakowski, M.J., Yonemori, K., Chen, D.T., Klingbiel, D., Heinzmann, S., Le Tourneau, C.   +12 more
openaire   +1 more source

Infantile NTRK -associated Mesenchymal Tumors

Pediatric and Developmental Pathology, 2017
Pediatric fibroblastic/myofibroblastic lesions are a relatively common group of tumors with varying morphologies, for which the molecular mechanisms are becoming increasingly well characterized. Congenital infantile fibrosarcoma (CIFS), perhaps the most well studied of these lesions is characterized by a recurrent ETV6-NTRK3 gene fusion.
Jessica L, Davis, Christina M, Lockwood, Catherine M, Albert, Karen, Tsuchiya, Douglas S, Hawkins, Erin R, Rudzinski   +5 more
openaire   +2 more sources

NTRK Therapy among Different Types of Cancers, Review and Future Perspectives

International Journal of Molecular Sciences
Neurotrophic tyrosine receptor kinase (NTRK) has been a remarkable therapeutic target for treating different malignancies, playing an essential role in oncogenic signaling pathways.
Luis E Raez, Meri Muminovic
exaly   +2 more sources

Cost-effectiveness of NTRK testing strategies for detecting NTRK fusions in solid tumors in China.

Journal of Clinical Oncology
3131 Background: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in many solid tumors. With the inclusion of the targeted drug Entrectinib in China's national reimbursement drug list, the demand for NTRK testing has also increased.
Jian Wang, Lifeng Wang, Shenglei Li, Wen Chen   +3 more
openaire   +1 more source

EU-Zulassung für NTRK-Inhibitor

InFo Hämatologie + Onkologie, 2019
Die EU-Kommission hat fur den NTRC-Inhibitor Larotrectinib erstmals eine vollstandig tumoragnostische Zulassung ausgesprochen.
openaire   +1 more source

Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers.

Clinical advances in hematology & oncology : H&O
Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are implicated in various cancers, including those of the lung and thyroid. The prevalence of NTRK fusions is 0.1 to 0.3% in non-small cell lung cancer (NSCLC) and as high as 26% in pediatric papillary thyroid carcinoma.
David S, Hong, Alexander, Drilon, Lori J, Wirth   +2 more
openaire   +1 more source

BPI21-006: Timing of NTRK Gene Fusion Testing and Treatment Modifications Following NTRK+ Status Among U.S. Oncologists Treating NTRK+ Patients

Journal of the National Comprehensive Cancer Network, 2021
Landon Z. Marshall, Andrew J. Klink, Abhishek Kavati, Ruth Antoine, Sibyl Anderson, Bruce Feinberg   +5 more
openaire   +1 more source

The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer

International Journal of Molecular Sciences, 2022
Haixia Qin, Manish R Patel
exaly  

A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study

Case Medical Research, 2019
openaire   +1 more source

NTRK-rearranged spindle cell neoplasms are ubiquitous tumours of myofibroblastic lineage with a distinct methylation class

Histopathology, 2023
Liesbeth Cardoen, Francois Le Loarer, Alice METAIS   +2 more
exaly